These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22831964)

  • 1. The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors.
    Sławek J; Roszmann A; Robowski P; Dubaniewicz M; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Kurzawski M; Bandurski T; Białecka M
    Neurodegener Dis; 2013; 12(1):1-12. PubMed ID: 22831964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
    Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
    Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine and vitamin B12 levels related to MRI white matter abnormalities in Parkinson's disease dementia.
    Ozcan O; Cosar A
    Neurodegener Dis; 2013; 12(3):164. PubMed ID: 23235384
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes.
    Shen Y; Dong ZF; Pan PL; Xu G; Huang JY; Liu CF
    Neurol Sci; 2019 Sep; 40(9):1855-1863. PubMed ID: 31055730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease.
    Joki H; Higashiyama Y; Nakae Y; Kugimoto C; Doi H; Kimura K; Kishida H; Ueda N; Nakano T; Takahashi T; Koyano S; Takeuchi H; Tanaka F
    J Neurol Sci; 2018 Feb; 385():99-104. PubMed ID: 29406924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual rating of white matter hyperintensities in Parkinson's disease.
    Beyer MK; Aarsland D; Greve OJ; Larsen JP
    Mov Disord; 2006 Feb; 21(2):223-9. PubMed ID: 16161159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
    Anamnart C; Kitjarak R
    J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of vascular risk factors and white matter hyperintensities on the degree of motor impairment in Parkinson's disease].
    Derejko M; Sławek J; Wieczorek D; Dubaniewicz M; Lass P
    Neurol Neurochir Pol; 2006; 40(4):276-83. PubMed ID: 16967348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma homocysteine, folate and vitamin B12 levels in Parkinson's disease in China: A meta-analysis.
    Dong B; Wu R
    Clin Neurol Neurosurg; 2020 Jan; 188():105587. PubMed ID: 31733593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia.
    Song Y; Quan M; Li T; Jia J
    J Alzheimers Dis; 2022; 90(2):681-691. PubMed ID: 36155508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status.
    Shin J; Choi S; Lee JE; Lee HS; Sohn YH; Lee PH
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):315-21. PubMed ID: 22228726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum homocysteine and physical exercise in patients with Parkinson's disease.
    Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
    Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease.
    Chahine LM; Dos Santos C; Fullard M; Scordia C; Weintraub D; Erus G; Rosenthal L; Davatzikos C; McMillan CT
    Eur J Neurol; 2019 Feb; 26(2):246-e18. PubMed ID: 30169897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease.
    Aarsland D; Litvan I; Salmon D; Galasko D; Wentzel-Larsen T; Larsen JP
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1215-20. PubMed ID: 12933921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy.
    Tepedino MF; Diana F; Abate F; Avallone AR; Caterino M; Erro R; Pellecchia MT; Manara R; Barone P; Picillo M
    J Neurol; 2024 Oct; 271(10):6866-6875. PubMed ID: 39222284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism.
    Zhang L; Yan J; Xu Y; Long L; Zhu C; Chen X; Jiang Y; Yang L; Bian L; Wang Q
    PLoS One; 2011 Apr; 6(4):e19333. PubMed ID: 21556377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
    Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
    Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.
    Rodriguez-Oroz MC; Lage PM; Sanchez-Mut J; Lamet I; Pagonabarraga J; Toledo JB; García-Garcia D; Clavero P; Samaranch L; Irurzun C; Matsubara JM; Irigoien J; Bescos E; Kulisevsky J; Pérez-Tur J; Obeso JA
    Mov Disord; 2009 Jul; 24(10):1437-44. PubMed ID: 19452554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD).
    Song IU; Kim JS; Park IS; Kim YD; Cho HJ; Chung SW; Lee KS
    Arch Gerontol Geriatr; 2013; 57(3):288-91. PubMed ID: 23706974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.